Use Sativex as an adjunct
when patients’ first-line oral
anti-spasticity medications
are not enough1–3


Sativex has limited
contraindications and
requirements for dose






Patients with hypersensitivity to cannabinoids or to any of the excipients1


Patients with any known or suspected history or family history of schizophrenia, or other psychotic illness; history of severe personality disorder or other significant psychiatric disorder other than depression associated with their underlying condition1


Patients who are breastfeeding1



Patients with significant hepatic or renal impairment



Sativex can be administered to patients with mild hepatic impairment without any dose adjustment1

– Administration to patients with moderate or severe hepatic impairment is not advised due to the lack of information on the potential for accumulation of THC and CBD with chronic dosing1


The effects of Sativex may be exaggerated or prolonged in patients with impaired renal function. Frequent clinical evaluation by a clinician is recommended in these patients1



Elderly patients


No specific studies have been carried out in elderly patients, although patients up to 90 years of age have been included in clinical trials1


As elderly patients may be more prone to develop some CNS adverse reactions, care should be taken in terms of personal safety such as preparation of hot food and drinks1